Login to Your Account



Japan's regenerative medicine path opens doors to early stage work

By Nuala Moran
Staff Writer

Friday, May 23, 2014
LONDON – An expedited approval system for regenerative medicines coming into effect in Japan in November, will provide a possible route for cell therapy companies from around the world to get conditional approval and reimbursement on the basis of phase I/II data confirming safety and indicating a product is likely to be effective.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription